An efficient integrated bioprocess for the oxidation of limonene to perillic acid with Pseudomonos putida DSM 12264 was developed. Perillic acid is a promising candidate for natural preservation and pharmaceutical application. At elevated concentrations the monoterpenoic acid inhibits growth and biotransformation activity of P. putida DSM 12264. The maximum growth rate showed a linear decrease from mu = 1.43 h(-1) in the absence of perillic acid to complete inhibition at 165 +/- 7 mM perillic acid. The maximum specific activity of limonene-transforming resting cells revealed an exponential decrease from almost 8 U/g cdw without perillic acid to <0.5 U/g cdw at >25 mM perillic acid. A method for in situ product recovery (ISPR) based on anion exchange resin was established to overcome product inhibition. A column containing a fluidized bed of Amberlite IRA 410 Cl was coupled to the bioreactor and enabled product removal by continuously recirculating the unfiltered broth through the ISPR unit. This led to a cumulative perillic acid concentration of 187 mM (31 g/L) after 7 days, which represents the highest product concentration achieved in a microbial monoterpene oxyfunctionalization so far. The ISPR approach reduced the further downstream processing steps needed which yielded a 93% pure product with a loss of 2%. (C) 2009 Elsevier Ltd. All rights reserved.